Changes and clinical significance of serum tumor markers in patients with non-small cell lung cancer before and after gefitinib targeted therapy
10.3760/cma.j.issn.1008-1372.2018.06.022
- VernacularTitle:吉非替尼靶向治疗非小细胞肺癌前后血清肿瘤标志物的改变及临床意义
- Author:
Zhanqiang XIE
1
;
Keluo CHENG
;
Lishuang YU
;
Ke LIANG
;
Jie CHEN
Author Information
1. 广东医科大学附属医院心胸外科
- Keywords:
Carcinoma,non-small-cell lung/DT;
Quinazolines/AD;
CA-125 antigen/ME;
Carcinoembryonic antigen/ME;
Phosphopyruvate hydratase/ME
- From:
Journal of Chinese Physician
2018;20(6):889-892
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the changes and clinical significance of serum tumor markers in patients with non-small cell lung cancer before and after gefitinib targeted therapy.Methods 80 cases of non-small cell lung cancer patients in our hospital from June 2015 to May 2017 were divided into control group and observation group randomly,40 cases in each group.The control group were treated with docetaxel conventional chemotherapy,and the observation group were treated with gefitinib targeted therapy.The clinical treatment effect,changes of serum tumor markers cancer antigen125 (CA125),carcinoembryonic antigen (CEA),neuron specific enolase (NSE) and adverse reactions were observed and compared between the two groups before and after treatment.Results The effective rate and disease control rate of the observation group were higher than that in the control group,with statistically significant difference (P ＜ 0.05).The levels of serum tumor markers CA125,CEA and NSE in the control group and the observation group before treatment were not significantly different (P ＞ 0.05).After 1 months of treatment,the levels of serum tumor markers CA125,CEA and NSE in the two groups were all decreased,and the level of serum tumor markers,CA125,CEA and NSE in the observation group were lower than those in the control group,with statistically significant difference.The incidence of adverse reactions in the observation group was lower than that in the control group (P ＜ 0.05),with statistically significant difference.Conclusions Gefitinib is effective in the treatment of non-small cell lung cancer.It reduces the level of serum tumor markers CA125,CEA,NSE,and reduces postoperative adverse reactions.It is worthy of clinical application.
